Skip to search formSkip to main contentSkip to account menu

Plasma cell dyscrasia

Known as: plasma cell disorder, cell dyscrasias plasma, cell dyscrasia plasma 
National Institutes of Health

Related topics

Related topics

14 relations
Familial Hemophagocytic LymphocytosisLeukemia, Monocytic, ChronicM5b Acute differentiated monocytic leukemiaMalignant histiocytosis

Narrower (3)

Multiple MyelomaPlasmacytomaSolitary Osseous Plasmacytoma

Broader (1)

Paraproteinemias

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients
Following the publication of this article, the authors noted that Patrick M. Vanderboom was inadvertently omitted from the author… 
2016
2016
Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias
Acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder that may cause life-threatening hemorrhages in patients with… 
Review
2012
Review
2012
Defining the Role of Renal Transplantation in the Modern Management of Multiple Myeloma and Other Plasma Cell Dyscrasias
Plasma cell dyscrasias (PCD) are due to an abnormal proliferation of a single clone of plasma or lymphoplasmacytic cells leading… 
Review
2006
Review
2006
Characterization of familial Waldenstrom's Macroglobulinemia.
6558 Background: Waldenstrom's macroglobulinemia (WM) is a B-cell malignancy, recently defined by a consensus panel as… 
Review
2006
Review
2006
Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population.
This study evaluated serum kappa and lambda free light chain (FLC) concentrations in a Veterans Affairs (VA) population. We… 
2001
2001
Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia
Recent studies have indicated a close relationship between inactivation of tumor suppressor genes (TSGs) and disease progression… 
1999
1999
Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
The use of serotherapy to treat patients with plasma cell dyscrasias (PCDs) has been sought by us and others. Candidate antigens… 
1996
1996
Acquired cutis laxa associated with a plasma cell dyscrasia.
Acquired cutis laxa (generalized acquired elastolysis) is characterized by skin laxity often with systemic involvement of the… 
Review
1987
Review
1987
Multiple myeloma and related plasma cell dyscrasias.
THE PLASMA cell dyscrasias (PCDs), of which multiple myeloma is the most common and also the prototype disease, represent a group… 
Highly Cited
1984
Highly Cited
1984
Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment--a prospective study of 160 patients.
Previous reports have shown that serum beta-2-microglobulin (S beta2M) is a reliable marker of presenting tumor mass, response to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)